V accines against viral diseasehave trad itionally relied on attenuated virus strains or inactivation of infectious virus. Subunit vaccinesbased on viral proteins expressedin heterologous systemshave been effectivefor some pathogens, but have ofien suffered from poor immunogenicity due to incorrect protein folding or modification. In this chapter we focus on a specific classofviral subunit vaccine that mimics the overall structure ofvirus particles and thus preserves the native antigenic conformation ofthe immunogenic proteins. Thesevirus-likeparticles (VLPs) have been produced for a wide range of taxonomically and structurally distinct viruses, and have unique advantages in terms of safety and immunogenicity over previous approaches. With new VLP vaccines for papillomavirus beginning to reach the market placewe argue that this technology has now 'come-of-age' and must be considered a viable vaccine strategy.
Introduction
There are many infectiousviruses that remain major threats to public health (seeTable 1).Where an effective vaccine exists,vaccination is usually the most cost-effective long-term protection against diseaseand spread for most viruses.The principle ofvaccination is to generate sufficient immunity to protect from infectious disease. Thus the vaccine stimulates the body's natural defensesagainst disease through use of a benign 'decoy' that mimics the virulent pathogen. The more similar a vaccine is to the natural disease, the better the immune response to the pathogen on subsequent exposure. In general, resistance to virus infection depends on the development ofan immune response to antigens present on the surface ofvirions or virus-infected cells. Therefore identification ofprotective antigens is the first step in the development ofeffectiveviral vaccines.
Currently many successfulviral vaccines have been developed and are in use. These vaccines are predominantly based on live attenuated or inactivated viruses. The live attenuated vaccines such as measles, mumps, rubella, oral polio, smallpox, varicella and yellow fever are a weakened form ofthe "wild" viruses. These attenuated virus vaccines rely on limited replication ofthe virus in the host following vaccination. Immune responses induced are similar to those from natural infections and often these vaccines are effective after a single dose. However, such vaccines may cause severe reactions in some patients, which are ofien the result ofthe limited replication ofthe att enuated virus following vaccination. In contrast to attenuated live virus vaccines, inactivated (or killed) vaccines can not replicate, as their genetic material or overall structure are purposefully destroyed. These vaccines are safer than live vaccines but generally not as effective, dosesasantibodytiter falls overtime.Theylackthe self-boostingqualities ofliveattenuatedvaccines but are saferin the sensethat the inherent dangersassociated with virus replicationare avoided. Thesevaccines are madeaswhole cellvaccines (suchasInfluenza,polio,rabiesand hepatitisA) or asfractionalor subunit vaccines such ashepatitisB. Subunit vaccines are basedon the delivery of only a limited number of viral proteins,often the major protein in the capsidor envelope that is sufficient to conferprotectiveimmunity. Thesevaccines arean incrementalstep saferthan inactivated vaccines becausesubunit vaccines can be prepared independent to the culture of replicating virus. Indeed, any remaining possibilityof incomplete inactivation or batch to batch variation in the safetyof the vaccineis eliminated. However, subunit vaccines havetraditionally suffered from one important drawback; often singleproteins when expressed and purified in the absence ofother viral componentsare less immunogenicthan those that areincorporated into infectious virus.Thisisprobablybecause a proportion of this protein ispresentin a misfoldedconformation relative to the nativeprotein. Thus, more doseswith higher amounts of antigen are required to achievethe samelevel ofprotection. A majoradvance in subunit immunogenproduction hasbeen assembly ofproteinsasvirus-like particles (VLPs) usingprotein expression technologyin yeast, insect or mammalian cells. VLPs are a highly effective type of subunit vaccines that mimic the overallstructure of virus particles without any requirement that they contain infectiousgeneticmaterial. Indeed, manyVLPslack the DNA or RNA genome of the virus altogether, but havethe authentic conformation of viral capsidproteins seenwith attenuated virusvaccines, without anyof the risksassociated with virus replication or inactivation.
VLP preparations are all based on the observation that expression of the capsid proteins of manyviruses leadsto the spontaneousassembly ofparticlesthat arestructurallysimilarto authentic virus.':' In practicalterms,the fact that VLPsmimic the structure of virusparticlesusually means that VLPsshouldelicitstronghumoralresponse and that lowerdoses of antigenrelative to subunit vaccines aresufficient to elicitsimilarprotectiveresponse. In addition to their abilityto stimulate B cell mediated immune responses, VLPshavealso been demonstrated to be highly effective at stimulatingCD4 proliferative and =(CTL) responses.l? Thisfeatureof VLPvaccines is likely to be a major contribution to their effectiveness in the field. It is also becomingincreasingly clear that preciseprime-booststrategies canbe important to how effective vaccinationisasa strategyto control disease.Therefore, the addition of VLPto the 'arsenal' of vaccine strategies for anydisease extends the type ofprime-boostregimethat can beemployed.
To date, VLPs have been produced for many differentviruses that infect humans and other animals (seeTable2 and review)," One of the most strikingfeatures of this group is that it is extremely diverse in terms of the structure of the individualviruses. It includesviruses that havea singlecapsidprotein, multiplecapsidproteinsand thosewith and without lipid envelopes. Clearly not allofthe VLPs that are generated to date are appropriate vaccine targets, some VLPs have been generated to facilitate in fundamental understanding of virus assembly process, morphogenesis or architecture ofviruses. However, an important point remains that the structure of the target virion is not limiting to the successofVLP production. Although various expression systems have been employed for VLP production, this chapter will mainly focus on insect cell culture produced VLPs that are being developed as candidate vaccines. The rationale behind this is that among all expression systems, insect cells, together with baculovirus expressing system, appear to be one of the most promising for VLP technology for development ofviral vaccines ( Fig. 1) . 
Insect Cells and Baculovirus Expression System as Preferred System for VLP Production
As stated above, a varietyof protein expression systems are available to express recombinant proteins and particles. Howevercertain criteriafor generationofVLPs as prophylacticvaccines, particularly forhumanviralinfection,mustbe considered. In orderforaVLPto bearealisticvaccine candidate, it needs to be produced in a safeexpression systemthat is easyto scaleup to large-scale production.Table2 shows baculovirus expressed/insect cellproducedVLPsthat havebeendemonstrated to be highlyimmunogenicand potential vaccine candidates.Thisinsectcell-based protein production systemhas manyadvantages for VLP production. Firstly, extremely largeamounts of correctly folded recombinant proteins can be produced in high-density cell-culture conditions in eukaryotic cells. Secondly, baculovirus expression systems havebeen developedfor expression of multiple foreign proteins simultaneously from a single recombinant virus facilitating capsid assembly in each infectedcell. Thirdly. asthe insectcellsthat are usedfor vaccine production can be cultured without the need for manunalian cellderivedsupplements. the risksof coculture of opportun istic pathogens is minimized. Fourthly. the baculovirus used for recombinant protein expression has a narrow host range that includesonly a fewspecies ofLepidopteraand therefore represents no threatto vaccinated individuals. Finally the baculovirus system is amenable to scale-up for largescalevaccine production,"
VLPsProduced forStructurally Simple Non-Enveloped Viruses
For a number ofnonenveloped virusesviral capsidsare formed by only one or two major proteins and thus are relatively easyto manipulate for generation of VLPsbyheterologousexpression systems. Examplesofthese are the VLPsformed by the expressionofthe major capsidprotein of Papillomaviruses, Parvoviruses, Calciviruses, Circovirses, Polyomaviruses and Hepatitis E virus ( Table 2 ). All of these viruses are nonenveloped and have a single, virallyencoded protein that forms the major structural component of the virion. Papillomavirus VLPs are among the most completelystudied ofthis collection of VLPs and are at the most advancedstagewith respectto production ofa usefulvaccine. VLP ofPapillomavirusesare formed from the over expressionof the major capsidprotein Ll. lO • 12These particlesare highly immunogenic and are ableto stimulate both humoral and cellmediated immune responses.P'" Human Papillomavirus (HPV) isthe leading causeofcervicalcancer.Globally, approximately70% ofall cervicalcancer casesareassociated with two serotypesofHPY, HPV-16 and HPV-lS. VLPsproduced in insect cellshavebeen used successfully for Phase I and II human clinicaltrials in largenumbers and were shown to be highly efficacious. 1S • 19 Moreover, GlaxoSmithKline's cervicalcancervaccinecandidate (Cervarix:"') targeting HPV 161IS iscurrentlyundergoingPhaseIII clinicaltrialsinvolvingmore than 30,000women worldwide. In this Phase III randomized, double-blinded trial conducted in multiple centres in Denmark, Estonia. Finland, Greece. the Netherlands and the Russian Federation. All vaccinees receivedthe HPV VLPs(HPV-16I1S AS04) asfollows: 15S 10-14yearsold healthygirls and 45S 15-25 yearsold young women receivedthe candidate VLP vaccineaccording to a 0,1,6 month schedule and anti-HPV antibody titers wereassessed. At month seven 100 per cent seropositivity wasachievedin both groups for HPV 16 and IS although average antibody titers for both HPV typeswereat leasttwo-foldhigher in 10-14 year-oldgirls.Thevaccinewastolerated byallpatients and no vaccinerelated seriousadverseeffectswere detected. Further, the follow-upsmdy clearly demonstrated the sustained efficacy of HPV-16I1S VLPs up to 4.5 years. 19 ,20 In conclusion, the bivalent HPV vaccine is highly immunogenic and safe and induces a high degree ofprotection against HPV-16 and HPV-lS infection and associatedcervicallesions.
Thesestudiesarenot onlyan important demonstrationofthe effectiveness ofHPVVLP vaccine, and that multi-serotype VLPs are effective, but also highlight the fact that insect cell produced VLPsare a realisticalternativeashuman vaccines againstviraldisease. It should alsobe mentioned at this point that a tetravalent (HPV-61III1611S)VLP vaccine, Guardasil'" (Merk),produced in yeastcellswasapproved by FDA in]une 2006 for use in women aged 9-26.
VLP vaccinesfor variousdiseases causedby parvovirusinfections are alsoat an advancedstage although as yet none have undergone such large scaletrials as those reported for HPV. Synthesis ofmajor structural proteins VP2 ofcanine parvovirus (CPV) and porcine parvovirus (PPV) led to assembly ofVLPs in insect cells. 21 . 22 Vaccinationtrials of CPV VLPs in dogs and PPV VLPS in pigswere highly encouraging.i':" In one efficacy assaydogs that receivedaslittle as or 10~or 25~ofCPV VLP werecompletelyprotected from virus infection when challengedwith virulent virus. Furthermorea singlesubcutaneousdose00~sameCPV VLP with 50~ISCOM adjuvant wasableto protect mink againstchallengewith the anti-genically similarvirus,mink enteritisvirus (MEV),2l Similarlyit has been reported recently that a singleimmunization with 0.7~ofPPV (porcine starin) VLPs yielded complete protection in targeted animals against infectious PPV strains.P Indeed microgram doses ofVLPs in gilts were not only highly immunogenic. but were alsoveryefficientin preventing trans-plancentalvirus transmission and significantly reduced the number of reproductive failures. In addition, the feasibilityof safelarge-scale production of the porcine parvovirusVLPvaccine hasbeen establishedcomplyingwith the EuropeanPharmacopoeia requirements,"
Calicivirusstudies have relied heavilyon the production of proteins in heterologous systems mainly due to the fact that it is not yet possible to grow the virus in cell culture. Thus, VLP to Norwalk-like viruses have been extremely useful as sources of diagnostic antigen to monitor diseaseoutbreaks. Norwalk virus VLP have also been shown to be effective at stimulating IgG, IgA and humoral responsesin mice. 24 • 2s Preliminary PhaseI trials in humans to test the safetyand immunogenicity of insect cell expressed Norwalk virus VLPs has confirmed that they are both safeand effectively stimulate IgG and IgAresponses. 26.27 VLPsfor Hepatitis E havebeen assembled usinga truncated form of the viruscapsidprotein." In immunization studies in mice these VLPswereable to induce systemic and mucosalimmune responses following oral adminisrrarion.P" Furthermore, oral administration of the Hepatitis E VLPs to cynomologousmonkeys induced IgM, IgA and IgG responses and was sufficient to protect against infection and disease on challengewith virus," Thus there is clear potential for the application of theseVLPsas a vaccinefor hepatitis E.
VLPpreparationsto Circoviruses and Polyomavirusareat a less advanced stage.VLP formation hasbeen reported for Circovirusbut asyetno seriousattempt hasbeenmadeat vaccine production. Vaccination of rabbitswith VLPsfor humanJC virusin the presenceof adjuvantallowedproduction ofa hyperimmuneserumthat effectively neutralizedinfectiousviruspreparadons." However, in the absenceofadjuvant there was no response. This pattern of responseis unusualfor VLPsin general,which often stimulatestrong immune responses evenin the absenceofadjuvant.Indeed, VLPs of murine polyomavirus were able to stimulate a strong immune responsein the absence of adjuvant when administered as a single 610 ng dose. 32 Intriguingly, these particles appear to be particularlystablewith no alteration ofparticle morphology or reduction in immunogenicity even after 9 weeksstorageat room ternperature.P
VLPs ofStructurally ComplexViral Capsids with Multiple ProteinLayers
Viral particles that contain multiple interacting capsid proteins present more of a technical challengethan those that are formed by one or two major capsidproteins. Particularly, it is far more difficultifthe assembling proteins of capsidsare encoded by multiple discretemRNAs, but not processedfrom a singlepolyprotein as in the caseof picornaviruses. This is due the fact that for efficientassembly of a VLP the interacting capsidproteins must be expressed in the vicinity to each other, in other words in the samecell Assembly of VLPsbyprocessingof polyproteins have been achievedboth for poliovirus" and for InfectiousBursaldiseasevirus" usingthe baculovirus expressionsystem. More complex assembly of multilayered, multiprotein VLPs have also been efficiently produced for the members of the Reoviridae. Theseviruseshave capsidsmade up of concentric layers of different capsidproteins. Co-expressionin insect cellsof2-4 ofthese capsid proteins, depending on the virus and the particle made, has allowedthe production ofVLP that are empty of the segmented dsRNA viral genome, but are otherwise indistinguishable from authentic viral particles. 4 • 35The first member of the Reouiridae for which VLPs were described is Bluetongue virus (BTV), an insect transmitted animal virus. This remains the systemin this familyfor which the largestvarietyofdifferentVLPsand recombinant singleantigen subunit immunogens made by baculovirus expression systems has been tested. In addition, the requirement for efficientco-expression of viralcapsidprotein in the sameinsect cellin this systemhas resulted in the development ofbaculovirus multigeneexpression vectors.36.37We will focuson this system in somedetail asit highlightsboth the effectiveness ofVLP vaccines and someof the technological advances that havebeen made for the production ofVLP with complexarchitecture.
Bluetongue disease affects mainly sheep and cattle and is classified as an emergingdiseasein Europe." The disease is causedby bluetongue virus,BTY,which has a multi-layered icosahedral structure formed by nonequimolar amounts of sevenviral proteins (VP1-VP7). Three of these structural proteins (VP1,VP4, VP6) are dispensable for the formation of VLPsas they playonly an enzymaticrole in the virus transcription rnachinery.P The remainingfour structural proteins (VP2, VP5, VP3 and VP7) are organisedin two capsids. The inner capsidactsasa scaffold for the assembly of outer capsidthat is responsible for cellentry and hence contains the major candidate for virus neutralisation." Expression of all four major structural proteins of BTV was achieved by construcing a baculovirus that simultaneously expressed all four proteins.YThe advantage of this approach over co-infection with several baculoviruses each expressing a single protein is that equivalent conditions are achievedin all infected cells. Thus assembly ofVLP is more efficientasexpression 120 100
80
-. · -10 J,g VlP · · ·. · · 5OI'll VLP is controlled at the level of the cell. rather than the level of the culture as is the case with mixed infections. BTV VLPs (Fig. 2) VLPs from two different serotypes were combined to vaccina te the same animal. In these animals VLPs vaccination provided complete protection against the rwo vaccine serorypes and also partial protection fromchallenge with relatednonvaccine serotypes.The protectiveefficacy ofvaccination in thesetrialsextendedovera long(14 month) period.P'Ihis observationraises the possibilitythat a broad spectrumvaccine againstall 24 BTV serotypes is a possibilitybycombiningVLPsfrom a relatively smallnumber of serotypes.
The BTV system also demonstratesthe efficiency ofVLP vaccines relative to immunization with subunit vaccines based on dissociated antigens or unassembled recombinant antigens. In addition the assembled VLPsthe two componentsofthe BTV outer capsid, VP2 and VP5, were alsopreparedand testedin vaccination studies.While 100~VP2,the majorserotypedetermining antigen,wasonlypartiallyprotectiveforashort duration (75days) againstvirulentviruschallenge, 50~ofVP2 combined with 25~VP5 was protective." In contrast, 10~VLPs (containing only 1-2~VP2) affordeda better level of protection for a much longer duration." Thesestudies demonstrate that assembly of antigensinto VLPsresultsin a more effective immunogen than deliveryof separately isolatedproteins.
In addition to BTV, VLP have also been produced for rotavirus, another member of the Reoviridae. Intriguingly, VLPsformedfrom the twoinner structuralproteinsaloneof the rotavirus capsid have been shown to be effective immunogens in animal modelsY-48Indeed in mice even intrarectal immunisationwhich inducesa localmucosalresponse issufficient for protection from rotavitus infection .v The data from these immunogenicityexperiments are encouragingand it is possible rotavirusVLP mayprovidea viablealternative to the livevitus vaccine for rotavitus.
VLPs from Viruses with LipidEnvelopes
Manypathogenicviruses suchasInfluenza, HIV and HepatitisC aresurroundedbyan envelope, a membranethat consists of a lipid bilayerderivedfrom the host cell,insertedwith vitusglycoprotein spikes. Theseproteins are the targetsofneutralizingantibodiesand areessential components ofvaccine. Due to the inherent properties of lipid envelope, assembly ofVLPs in insect cellsfor thesevitusesis a different type oftechnicalchallenge to those produced for vituseswith multiple capsids. Nevertheless, efficient formation ofVLPs of a number of enveloped viruses in insectcells hasbeen reported.Forexample, VLPsof HepatitisC virus,several retroviruses, SARSCoronavirus and influenza A havedemonstratedcorrectassemblyof the the lipidenvelope with theglycoproteins inserted.so-ss Indeed,for retroviruses, it hasbeenpossible to producehybridVLPsthat contain the gagcapsidprotein fromone virus(SIV) and the envelopeprotein from another (HIV)S6 in insect cells. Although none of the retrovirus derivedVLPsare yet at the stagethat they are beingusedin clinicalvaccinetrials,initial experiments in anitnalmodelsare promising. s7 . s8
VLPs for SARS Coronavitus as a basisfor vaccinationwere produced rapidlyfollowing the SARSoutbreak in 2002-2003. S4.SS Howeverthe control ofSARS Coronavirusbyepidemiological measures, continued lackof re-emergence of the virus,and difficulties workingdirectlywith the virus haveseverely limited the developmentof SARSVLPs as vaccine. Despite this, anti-serum raisedin mice againstinsect cellderivedSARSVLPswereableto neutralizea retroviruspseudotyped with the SARSS protein (Fig.3) .
The Hepatitis C VLPs (Fig. 1 )havebeen tested in miceand baboonsand shown to be effective at stimulatingboth cellularand humoralimmune responses.?·S3oS9 In one experiment, 6-8 weekold female BALBlc micewere immunizedintramuscularly three times,at three week intervalswith 20~insect cellderivedH CV VLP, produced byco-expressing HCV coreE1-E2. Because of the lackofasuitableanimalmodelfor H CV infectionsa recombinantvaccinia vitusexpressing HCV structural proteins (vvHCV.S)wasusedasa modelsystem. Vaccinated micewerechallenged three daysafterthe finalimmunizationwithvvHCV.S and then five dayslaterthe ovaries ofinfectedmice wereharvested and the vaccinia virustitre determined. Fiveout ofseven vaccinatedanimalshad no detectablevacciniavirus in the ovaries at this point. The remainingtwo anitnalshad five logs lowervacciniatitres compared to control mice'? In addition, this study wasable to demonstrate that the VLPsefficacy wasbasedlargely on its stimulation of CD4+ and CD8+ T-cell responses. A further study in baboonshas demonstrated that the VLPsare welltolerated and can stimulate broad and long-lastingHCV targeted immune responses.P B 600 , 500 Figure 3 . Summary of production and testing of VlPs to SARS coronavirus. A) left, cartoon and right, electron micrograph of VlPs produced by co-expression of E, M and S proteins of SARS coronavirus . These VlPs were used to raise anti-sera in mice and the ability of these anti-sera to protect against infection with a SARS 5 protein pseudotyped lentivirus were assessed. B) le90 neutralising antibody dilution for SARS S pseudotyped lentiv irus, using sera from 3 mice immun ized with SARS VlP, rotavirus VlP and serum obtained from a SARS convalescent patient.
To date, the most structurally complicated enveloped virus particle that has been used to generate VLP is influenza.VLPs for InfluenzaA H9N2 and H3N2 have been produced by other groups.PThese studies have shown that expression of the major structural protein MI alone is sufficient result in the budding ofvirus-likevesicles from insect cells.? Also, co-expressionofMl with M2, HA and NA leadsto the assembly of influenzaVLP and MI-HA and MI-HA-NA VLPs confer protection from lethal challengewith the same type influenza A in mice. 60 • 61 VLP production was also successfully achieved by co-expressing HA, NA, MI and M2 from influenza virus A/Udorn/72 (H3N2) using a single recombinant baculovirus.P To date none ofthese influenza VLP havebeen tested in humans. However the potential that HA and NA could be incorporated directly into these VLP from circulating influenza strains without passage in tissue culture has particular advantage for the control of rapidly changing influenzaA virus.
Future andAlternative Directions
In addition to the use ofVLPs as direct immunogens, the efficiency with which they stimulate cellular and humoral responses has made them prime candidates as carrier moleculesfor the deliveryof epieopes, DNA and smallmolecules targetingother diseases. Thishas been facilitated by the excellent structural information that is often available for virus particlesallowingrational designof vaccines where epitopes are exposedon the surfaceof the VLP. Manyof the VLPsthat have been developedas vaccines in their own right have also been tested as delivery systems for other molecules. It is not possible here to providea full accountof this approach, as the literature on deliveryand display usingVLPsis at leastaslargeas that on VLP production for direct immunization (for reviewseeref 62). Howeverit is necessary at least to introduce this important area ofVLP-based vaccine development.The use ofVLPs as carrier molecules for epitopes for other diseases isnot limited to thoseVLPsthat areformed from the capsids of economically significant viruses. The reasonthat manyVLPsmakeexcellent carriermolecules for the delivery of epitopes in vaccines is most likely because the particulate VLP structure is readily taken up into antigen presenting cells and thus is able to prime long lasting CTL responses in addition to antibody responses. 6 .63.64 Certainly accumulatedevidence on VLP vaccines suggests that they are efficient at stimulating both cellularand humoral immune responses. H 64-66 Notable work has been done in this areawith both the hepatitis B core particles, human papillomavirus VLPsand parvovirus VLPsdisplayingT-cellspecific epltopesfromanother protein on their capsid. 5 .64-66.67 Thesestudies demonstrate that like bacterialepitope displaysystems VLPs are efficient stimulators of MH C class I and class II responses.v ThusVLPshavegreatpotential asepitope displaysystems for other diseases. Theonly majordrawbackfor this approachisthat the requirementof the capsidprotein to assemble often constrains the sizeof the foreign sequence that can be tethered to the VLP. One approach that maybe of use to overcome this constraint would be to link foreign protein sequences to capsidproteins in such a way that they extend the N or C termini of the protein and extendeither insideor outside to particle/" Ofcourse,this isonly suitablewhereone or both termini ofthe protein are exposedon the insideor outside faceof the capsid. So far, there are no VLP that we are awareof that havefullyexploitedthe potential of this approach but it has been successfully employedfor other protein-basedparticulate structures that are similar to VLPs in their stimulation of B-cell and T-cell responses and requirement for complexprotein-protein interactions for particleassembly/"?'
Perspectives: Myths andFacts
Despite the accumulatedevidence of the potential ofVLPs as potent immunogensfor many viralsystems that wehavediscussed, thereremains someresistance to the VLPapproachasageneral vaccinationstrategyfor diseases causedby viruses. In part this is due to some high profiledisappointing resultsfor VLP vaccines in the earlystages of development, for example an ineffective earlyvaccine for HIV basedon TyVLPS.72 Thisexampleraises a point of caution for VLPvaccine designers. In general. VLPs stimulate efficient cellular and humoral immune responses but, as with anyvaccine, they relyon the long term host response to be effective. VLPsdesignedto work in immunocompromisedindividuals need to overcome the samechallenges to efficient immune responseas any other vaccine approach. The notion that VLPsare ineffective vaccines is clearly a myth that isexplodedby the imminent release of two new VLP-based HPV vaccines. Indeed, the accumulateddata from the fieldsuggests that VLPsare more effective thanmanyother types of subunit vaccines, becausethey are more conformationally authentic and are saferthanmanylive viruspreparationsbecause they are usually freeof viralgeneticmaterial.VLPproduction doesnot appear to be limited to anyone type of virus or virusfamily, nor is it significantly limited by the complexityofthe virus particle."
The use of insect cells as a protein expression system offers excitingopportunities for the synthesis of conformationally authentic VLPs that are formed from the intracellularassembly ofmultiple proteins expressed in the samecell. The advantage of this system overothers used for protein expression is its capacityfor industrial scale synthesis of largeand multiple proteins and the fact that insectcells are the natural replicationreservoirfor manypathogenicviruses. Thusthe basiccellularmachinerythat normallyprocesses the infectiousform of the virusispresent within the expression system and available to produce authentic VLPs.
